News Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD Continue Reading Previous Letter to Shareholders and Corporate UpdateNext Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 Related Stories Digital Transformation News CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification News Wells Fargo Scandal Drove Borrowers to Fintech Lenders, UC Davis Study Suggests News CertiK Cements Institutional Presence After CEO’s Strategic Engagements in Hong Kong News UOB Hong Kong becomes first Singapore-based bank to sign MOU with HKTDC News INVEST FAIR Malaysia 2025 Spotlights Investor Trends, Multi-Asset Literacy, and Tech-Driven Platforms News Clara Technologies Announces Sales Buddi Launch on Google Play Store, Extending Global Reach of Quantum-AI Sales Platform
